Recent data from key phase III RCTs performed in China, Rationale-305 and ORIENT-16, show an OS benefit in patients with PD-L1+ unresectable GC/GEJC treated with PD-L1 inhibitors in combination with chemotherapy compared to placebo and chemotherapy [73,74]. Here, CD274 is linked to gastric cancer.